A Study of SHR-4375 in Subjects With Solid Tumors
This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.
Solid Tumors
DRUG: SHR-4375
Adverse events (AEs), From Day 1 to 90 days after last dose.|Dose limiting toxicity (DLT), From Day 1 to 12 months.|Maximal tolerable dose (MTD), From Day 1 to 12 months.|Recommended phase 2 dose (RP2D), From Day 1 to 12 months.
Progression free survival (PFS), From Day 1 to 12 months.|Objective response rate (ORR), From Day 1 to 12 months.|Disease control rate (DCR), From Day 1 to 12 months.|Duration of response (DOR), From Day 1 to 12 months.|Overall survival (OS), From Day 1 to 12 months.
This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.